Novo Nordisk acquisition of Emisphere Technologies
Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…
Coloplast acquisition of Nine Continents Medical
Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…
Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…
Abcam $180 million U.S. IPO of ADSs
Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…
Aligos Therapeutics $150 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…
Eargo $165.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9,029,629 shares of common stock of Eargo, Inc. at $18.00 per share …
Aziyo Biologics $50 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…
GoodRx Holdings $1.3 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…